Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06755992
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PF-06755992 is a cancer vaccine developed by Pfizer. It consists of a genetically engineered, replication-deficient chimpanzee adenovirus serotype 68 (AdC68) that encodes three tumor-associated antigens specific to prostate cancer: human prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), and prostate stem cell antigen (PSCA). The vaccine is designed to stimulate the immune system to recognize and attack prostate cancer cells expressing these antigens. It was investigated as part of a two-part immunotherapy regimen for advanced or metastatic prostate cancer, often in combination with other immunotherapies such as checkpoint inhibitors. Development was discontinued during preclinical or early clinical phases[1][2][3][4].
- Other names
- AdC68 Expressing PSA/PSMA/PSCA Vaccine
02
Targets
PSMA (Prostate-specific membrane antigen)PSA (Puromycin-sensitive aminopeptidase)PSCA (Prostate stem cell antigen)
Beyond the preview
Go deeper on PF-06755992.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06755992.